- Home
- CAPR vs ORGO Comparison
CAPR vs ORGO Comparison
Compare CAPR & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- ORGO
- Stock Information
- Founded
- CAPR 2005
- ORGO 1985
- Country
- CAPR United States
- ORGO United States
- Employees
- CAPR N/A
- ORGO N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- ORGO Biotechnology: Pharmaceutical Preparations
- Sector
- CAPR Health Care
- ORGO Health Care
- Exchange
- CAPR Nasdaq
- ORGO Nasdaq
- Market Cap
- CAPR 600.7M
- ORGO 376.8M
- IPO Year
- CAPR N/A
- ORGO N/A
- Fundamental
- Price
- CAPR $11.15
- ORGO $2.81
- Analyst Decision
- CAPR Strong Buy
- ORGO Buy
- Analyst Count
- CAPR 6
- ORGO 2
- Target Price
- CAPR $41.67
- ORGO $5.50
- AVG Volume (30 Days)
- CAPR 3.3M
- ORGO 1.6M
- Earning Date
- CAPR 05-13-2025
- ORGO 05-08-2025
- Dividend Yield
- CAPR N/A
- ORGO N/A
- EPS Growth
- CAPR N/A
- ORGO N/A
- EPS
- CAPR N/A
- ORGO N/A
- Revenue
- CAPR $17,363,588.00
- ORGO $458,760,000.00
- Revenue This Year
- CAPR $78.79
- ORGO $2.73
- Revenue Next Year
- CAPR $158.07
- ORGO $12.28
- P/E Ratio
- CAPR N/A
- ORGO N/A
- Revenue Growth
- CAPR N/A
- ORGO 5.35
- 52 Week Low
- CAPR $3.52
- ORGO $2.28
- 52 Week High
- CAPR $23.40
- ORGO $6.71
- Technical
- Relative Strength Index (RSI)
- CAPR 56.47
- ORGO 34.21
- Support Level
- CAPR $10.04
- ORGO $2.96
- Resistance Level
- CAPR $10.80
- ORGO $3.28
- Average True Range (ATR)
- CAPR 1.07
- ORGO 0.15
- MACD
- CAPR 0.20
- ORGO -0.02
- Stochastic Oscillator
- CAPR 87.16
- ORGO 30.06
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.